[A comparative gastroscopic study of lonazolac and indomethacin in healthy subjects].
In 9 healthy volunteers the effects of a 14-day treatment with lonazolac 300 mg b.i.d. on gastric and duodenal mucosa have been endoscopically compared with those of indomethacin 75 mg b.i.d. in a double-blind placebo-controlled trial. Lonazolac and indomethacin induced significantly more gastric and duodenal mucosal injuries (1.9 +/- 0.4 and 1.7 +/- 0.3) compared to placebo (0.9 +/- 1.0) (p less than 0.05). The validity of different procedures in predicting the deleterious effects of nonsteroidal antiinflammatory drugs on the human upper gastrointestinal epithelium is discussed.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005773:Gastroscopy; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced*; D011720:Pyrazoles / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; C017472:lonazolac; D007213:Indomethacin
Eine gastroskopische Vergleichsstudie mit Lonazolac und Indometacin bei gesunden Probanden.